Key result
Primary cardiac lymphoma lacks reported quantitative data on long-term clinical outcomes.
Why the study?
Primary cardiac lymphoma is a rare disease with limited data regarding treatment strategies and long-term outcomes.
Observational
Yes
Answers are grounded in this paper and cite their sources.
Long-term outcomes of primary cardiac lymphoma remain undefined; this cohort study leaves open the need for prospective survival data.
rimary cardiac lymphoma (PCL) is a rare disease with an incidence of 1% of primary cardiac malignancies and 0.5% of all extranodal lymphomas. hemotherapy continues to be the primary treatment in PCL, but there have been reports of other treatment strategies including radiation, immunotherapy, and surgery. Unfortunately, there is a paucity of data on PCL. This study aimed to address this lack of data by leveraging a contemporary national database.
No takes yet. Share an insight, caveat, or question.
Sultan et al. (2020) conducted an observational in Primary cardiac lymphoma (PCL). Primary cardiac lymphoma treatments (chemotherapy, radiation, immunotherapy, surgery) was evaluated on Long-term outcomes.
Synapse has enriched 10 related papers. Consider them for comparative context: